Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Current Leases (2021 - 2026)

Pliant Therapeutics has reported Current Leases over the past 6 years, most recently at $1.7 million for Q1 2026.

  • Quarterly Current Leases rose 122.18% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, up 122.18% year-over-year, with the annual reading at $1.4 million for FY2025, 166.97% up from the prior year.
  • Current Leases was $1.7 million for Q1 2026 at Pliant Therapeutics, up from $1.4 million in the prior quarter.
  • Over five years, Current Leases peaked at $2.6 million in Q3 2022 and troughed at $98000.0 in Q2 2024.
  • The 5-year median for Current Leases is $1.4 million (2025), against an average of $1.5 million.
  • Year-over-year, Current Leases tumbled 95.61% in 2024 and then surged 1150.0% in 2025.
  • A 5-year view of Current Leases shows it stood at $2.5 million in 2022, then tumbled by 46.36% to $1.3 million in 2023, then crashed by 58.88% to $542000.0 in 2024, then skyrocketed by 166.97% to $1.4 million in 2025, then increased by 18.38% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Current Leases are $1.7 million (Q1 2026), $1.4 million (Q4 2025), and $1.2 million (Q3 2025).